Despite the fact that CDK4/6 alterations are very common in many types of malignancies and that numerous preclinical studies on these agents have shown tumor suppressive effect, significant clinical benefits have only been demonstrated primarily in breast cancer and to a lesser extent, WDLPS/DDLPS [69,70,71]. The gene discussed is CDK4; the disease is breast cancer.